Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 177,704 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the transaction, the chief operating officer now directly owns 740,976 shares of the company’s stock, valued at $8,550,863.04. This represents a 19.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded up $0.40 during midday trading on Tuesday, reaching $11.83. 4,205,813 shares of the company’s stock traded hands, compared to its average volume of 5,754,317. Roivant Sciences Ltd. has a one year low of $9.69 and a one year high of $13.06. The stock has a 50 day moving average of $11.91 and a 200 day moving average of $11.55. The company has a market cap of $8.61 billion, a price-to-earnings ratio of 2.09 and a beta of 1.25.

Institutional Trading of Roivant Sciences

Institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its position in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares during the period. Rubric Capital Management LP raised its stake in Roivant Sciences by 15.0% during the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after buying an additional 3,000,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares during the period. Finally, DME Capital Management LP boosted its stake in shares of Roivant Sciences by 14.8% in the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after buying an additional 620,470 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, Bank of America lifted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.